The American Journal of Transplantation recently published a paper, documenting a first-of-its-kind treatment for midaortic syndrome, as performed by Khashayar Vakili, MD, of Boston Children’s Department of Surgery and Heung Bae Kim, MD, director of Boston Children’s Pediatric Transplant Center.
In the following blog Marcus Groff, father of the patient described in the Journal of Transplantation, writes about his daughter’s revolutionary surgery at Boston Children’s.
Two years ago my wife and I were anxiously waiting outside the NICU of our local hospital at four in the morning. Inside, our daughter Sofia was being monitored for several medical concerns, including dangerously high blood pressure. The nurses on staff assured us that Sofia was “a fighter” so when we drifted off to sleep later that morning we were exhausted, but joyful. We never saw what was coming, but then, you rarely do.
It would take a few days before the gravity of the situation became too obvious to ignore. While we fretted over our daughter’s high bilirubin and high blood pressure, something ominous was lurking. I couldn’t put my finger on it, but something wasn’t quite right. Still, we took our queues from the medical staff, which seemed confident our Sofia would pull-through. Only later, through tearful goodbyes, would the nurses confide that privately they feared Sofia wouldn’t make it.
We came to Boston Children’s for a second opinion of what was making Sofia so sick—what we got was a name for the phantom malady that was plaguing our daughter: midaortic syndrome (MAS). MAS occurs when the aorta, the main artery that delivers oxygen-rich blood throughout the body, is narrowed or damaged, which can often cause serious spikes in blood pressure by restricting blood flow to the kidneys. (A condition known as renovascular hypertension.)
We finally had a name for Sofia’s illness, but a larger question still loomed: How do you treat it? …